On May 28, 2025, Neumora Therapeutics held its Annual Meeting of Stockholders where shareholders voted on four proposals, including electing two directors and approving a reverse stock split. Notably, 134 million shares approved the reverse stock split proposal, which will be between 1-for-5 and 1-for-30.